Market Scenario
Globally the market for Parkinson’s disease therapeutics is increasing rapidly. The major factor that drives the growth of the market is the increasing growth in aging population. Furthermore, increasing environmental factors & genetic heredity is increasing the growth of the Parkinson’s disease therapeutics market. Moreover, the risk of Parkinson’s disease increases with age, and the disease mainly affects a person over 50 years of age. The treatments for the Parkinson’s disease are mainly symptomatic and no curative treatment options.
However, expiration of patent drugs is expected to hamper the market growth during the forecast period.

Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/1572
Key Players for Global Parkinson’s Disease Therapeutics Market
Market Research Future (MRFR) recognizes the following companies as the key players in Parkinson’s Disease Therapeutics Market: There are plenty of large and small market players which operate in this market all over the globe.
Salix Pharmaceuticals, GlaxoSmithKline Plc, Impax Laboratories, LLC, Teva Pharmaceutical Industries Ltd, Novartis AG, Orion Corporation, Mylan N.V., Par Pharmaceutical, Cipla Inc., Daiichi Sankyo, Apotex Inc., Wockhardt Limited and Others.
Segments for Global Parkinson’s Disease Therapeutics Market
The Global Parkinson’s Disease Therapeutics Market is segmented on the basis of treatment type and end-user. The global Parkinson’s disease therapeutics market by treatment type is segmented into medication and surgical therapy. Medication segment is segmented further into dopamine precursors, peripheral decarboxylase inhibitors, COMT inhibitors, MAO inhibitors, and others. Surgery therapy is further segmented into deep brain stimulation (DBS) and carbidopa/levodopa enteral suspension.